An expedited approach towards the rationale design of non-covalent SARS-CoV-2 main protease inhibitors with in vitro antiviral activity
Naoya Kitamura(University of Arizona), Jun Wang(Rutgers Sexual and Reproductive Health and Rights), M. Sacco(University of South Florida), Julia A. Townsend(University of Arizona), Sara Cherry(California University of Pennsylvania), Yanmei Hu(University of Arizona), Chunlong Ma(University of Arizona), D. Schultz(University of Evansville), Yan Xiang(Sichuan University), Fushun Zhang(The University of Texas at San Antonio Health Science Center), Michael T. Marty(University of Arizona), Yu Chen(University of South Florida), Xiangzhi Meng(University of California, Los Angeles), Xiujun Zhang(University of South Florida), Adis Kukuljac(University of South Florida)
Cited by 2
Related Papers
Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications
|Science|2020|1.7k
SETDB1: a novel KAP-1-associated histone H3, lysine 9-specific methyltransferase that contributes to HP1-mediated silencing of euchromatic genes by KRAB zinc-finger proteins
|Genes & Development|2002|1.3k
Targeting histone deacetylase complexes via KRAB-zinc finger proteins: the PHD and bromodomains of KAP-1 form a cooperative unit that recruits a novel isoform of the Mi-2α subunit of NuRD
|Genes & Development|2001|523